EP1598339A1 — 1-(4-amino-cyclohexyl)-1,3-dihydro-2h-benzimidazole-2-one derivatives and related compounds as nociceptin analogs and orl1 ligands for the treatment of pain
Assigned to Euro Celtique SA · Expires 2005-11-23 · 20y expired
What this patent protects
It is an object of certain embodiments of the present invention to provide compounds useful as analgesics, anti-anflammatories, diuretics, anesthetics and neuroprotective agents, anti-hypertensives, anti-anxioltics; agents for appetite control; hearing regulators; anti-tussives, …
USPTO Abstract
It is an object of certain embodiments of the present invention to provide compounds useful as analgesics, anti-anflammatories, diuretics, anesthetics and neuroprotective agents, anti-hypertensives, anti-anxioltics; agents for appetite control; hearing regulators; anti-tussives, anti-asthmatics, modulators of locomotor activity, modulators of learning and memory, regulators of neurotransmitter and hormone release, kidney function modulators, anti-depressants, agents to treat memory loss due to Alzheimer's disease or other dementias, anti-epileptics, anti-convulsants, agents to treat withdrawal from alcohol and drugs of addiction, agents to control water balance, agents to control sodium excretion and agents to control arterial blood pressure disorders and methods for administering said compounds. <??>The compounds of the present invention are useful for modulating a pharmacodynamic response from one or more opioid receptors (ORL-1, mu , delta and kappa ) centrally and/or peripherally. The response can be attributed to the compound stimulating (agonist) or inhibiting (antagonist) the one or more receptors. Certain compounds can stimulate one receptor (e.g., a mu agonist) and inhibit a different receptor (e.g., an ORL-1 antagonist). <??>The present invention in certain embodiments comprises compounds having the general formula (III): <CHEM> wherein D is a 5-8 membered cycloalkyl, 5-8 membered heterocyclic or a 6 membered aromatic or heteroaromatic group; the other substituents are defined in the claims.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.